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Introduction
The measurement of estrogen receptor alpha (ERα) has
become an important routine procedure in breast carcinoma,
because the presence of ERα in the tumor indicates a high-
er chance of response to anti-estrogen hormonal therapy.20
Positivity for ERα is therefore correlated with a better prog-
nosis.24 Biochemically, PR is one of the end products from
estrogenic stimulation in the target tissues.10,31,38 Thus, the
demonstration of PR suggests the presence of ER by default.
The presence of PR, in addition to ER suggests further the
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A retrospective study comparing the estrogen receptor
(ER) α subtype and progesterone receptor (PR) profile
of breast carcinomas amongst 1625 cases over 2.5 years
was carried out. Strictly speaking it is generally
believed that breast carcinomas can biochemically
express PR only if they are ER-positive. However, a
few ERα-PR+ cases do exist paradoxically. This class
of tumors was the focus of our study in which we
looked at the possible reasons for such an
immunophenotype and compared it with a group of
ERα+PR+ breast carcinomas. An internationally rec-
ognized immunohistochemical method employing
monoclonal antibodies against estrogen and proges-
terone receptors was used. Correlations with estab-
lished risk factors i.e. menopausal status, grade,
tumor size and lymph node status were analyzed for
our study group (ERα-PR+) and compared with a con-
trol (ERα+PR+). Out of the total 1625 cases, 29.91%
(486) were ERα+PR+, 5.11% (83) were ERα+PR-,
56.86% (924) were ERα-PR- and 8.12% (132) were ERα-
PR+. Patients’ age was significantly lower in the ERα-
PR+ group (P=0.002). Statistical analysis of the grad-
ing between the two study groups revealed no signif-
icant difference (P=0.091), although the ERα-PR+
group contained significantly more poorly differenti-
ated tumors than the ERα+PR+ one (P=0.032). Tumor
size was also significantly larger in the ERα-PR+ than
in the ERα+PR+ group (P=0.046). The frequency of
lymph node metastases was independent of receptor
profile. In conclusion, our study group does exhibit
characteristics which are suggestive of a distinct
breast cancer phenotype (ERα-PR+) with a different
etiology and prognosis.(Pathology Oncology Research
Vol 12, No 4, 223–227)
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likelihood of response to hormonal therapy, presumably
because the presence of PR indicates an intact and function-
ing ER pathway.21 There is general agreement that approxi-
mately half of the women whose tumors have detectable
ERα will obtain objective remission from some form of
endocrine therapy.5 This number increases to three quarters
when PR, an estrogen-induced protein is included.5 It has
been suggested that since the synthesis of PR denotes a
functional ER, its measurements with ER can be of greater
value than the measurement of ER alone.5 The prognostic
impact of ER status is still under investigation but seems to
indicate that significant amounts of ER in breast tumors are
associated with a longer disease-free survival.2,12 It is pro-
posed that after some cell divisions and while still retaining
some proliferative capacity the ER starts to get expressed.1
This triggers the expression of PR. Once PR is synthesized
and binds progesterone, it inhibits several genes related to
cellular proliferation. This explains the growth characteris-
tics of most breast cancers, e.g. in well-differentiated
ERα+PR+ tumors, PR expression would exhibit a feedback
inhibition on ERα+ cells and would slow down the growth
process. Since many poorly differentiated tumors do not
express ER and, consequently, PR, they would remain insen-
sitive to the blocking action of PR. 
Despite such remarkable progress in this area, there
remain a number of unanswered questions regarding the role
of the hormone receptor in the regulation of breast cancer
cells. One of these questions concerns the existence of a
small percentage of patients with ERα-negative but PR-pos-
itive tumor. This is so because it is generally accepted that
the level of PR in mammary gland and its tumors is regulat-
ed by estrogens, presumably through the estrogen recep-
tors.16-18 It is believed, therefore, that the detection of both
receptors in breast cancers indicates that the complex mole-
cular events that are involved in the regulation of protein
synthesis and cell growth by estrogens are intact.16-18 So the-
oretically speaking, tumors that do not contain ER, but con-
tain PR, should not exist. However, some studies have iden-
tified a small percentage of such tumors, usually between 2%
to 6%.13,21,25,28,37 Others reported the incidence for this sub-
group of breast cancer to be 5% to 10%.14,17 The reasons for
such a receptor profile are unclear. In this study, we looked
at the relative frequency, morphologic characteristics and
possible reasons for such an immunophenotype by using an
internationally recognized robust immunohistochemical
method. With the recent development of monoclonal anti-
bodies against nuclear estrogen and progestin receptor epi-
topes,9,23 immunohistochemical measurements have increas-
ingly gained momentum, and several groups have studied
their prognostic relevance.24,26 Clear benefits of this tech-
nique are visualization of the receptor protein to disclose
tumor heterogeneity, independence of receptor-masking
estrogens of endogenous and exogenous origin, no interfer-
ence of data with receptor-blocking substances, and minimal
tumor quantity required for analysis. We looked at the group
with ERα-PR+ phenotype in a major tertiary care referral
center and compared its frequency and demographics with
those of the ERα+PR+ group to explain the possible reasons
for the former phenotype.
Materials and Methods
Sample size
This study group consisted of 1625 consecutive breast
biopsy and mastectomy specimens received for ERα/PR
evaluation by immunohistochemistry in the years 2001-2003
(over 2.66 years) at The Aga Khan University Hospital,
Department of Pathology, Karachi. In this study only classic
infiltrating ductal carcinomas (NOS) were included and the
histological grading was performed according to the modi-
fied method described by Bloom and Richardson,4 taking 3
criteria into consideration, i.e. tubule formation, nuclear
pleomorphism and mitosis, each given a point ranging from
1-3. Grades were allocated as follows: 3-5 points (grade 1,
well-differentiated), 6-7 points (grade 2, moderately differ-
entiated) and 8-9 points (grade 3, poorly differentiated).
Immunohistochemistry
Immunohistochemical (IHC) analysis of ERα and PR
was performed on formalin-fixed, paraffin-embedded
tumor tissue. Three to four micrometer thick sections were
cut from one representative block for each case and con-
trol. A microwave antigen retrieval method was applied
using citrate buffer (pH 6.0) or target retrieval solution.
Endogenous peroxidase activity was blocked with 3%
H2O2. The slides were then incubated with monoclonal
antibodies against estrogen and progesterone receptor (ER
clone ID5 and PR clone IA6, ready-to-use; DAKO, Den-
mark). Envision system was used to detect the reaction
(Figure 1). All cases were run with known positive con-
trols for each antibody and, where possible, with normal
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Figure 1. Grade 2 infiltrating ductal carcinoma of the breast
stained with a monoclonal antibody against ERα subtype (clone
ID5). Note a diffuse strong nuclear staining consistent with
strong positive ER status. x40
Figure 2. Normal breast tissue in the same tumor block was used
as internal built-in control at the time of block selection. x10
breast lobules adjacent to tumor to assess built-in control
(Figure 2). For negative control, the primary antibody was
omitted for each run.
Staining and semi-quantitative scoring
The immunohistochemical localization of ERα and PR
was scored in a semi-quantitative fashion, incorporating both
the intensity and the distribution of specific staining as
described elsewhere.13 Evaluation was recorded as percent-
age of positively stained tumor cells in each of five intensity
categories denoted as zero (no staining), 1+ (weak but
detectable), 2+ (mildly distinct), 3+ (moderately distinct) and
4+ (strong). For each tissue, a value designated as HSCORE
was derived by summing up the percentages of cell staining,
each intensity multiplied by the weighted intensity of stain-
ing. An H score of ≤74 was taken as negative, 75-99 as
weakly positive, 100-119 as intermediate positive, while 120
and above was interpreted as strongly positive. 
Correlations with established risk factors as tumor size,
grade, lymph node status and menopausal status, were ana-
lyzed for our study group (ERα-PR+) in comparison with
those for the ERα+PR+ group. Statistical analysis was
done using the SPSS (11.0) software.
Results
Out of the total 1625 cases, 29.91% (486) were
ERα+PR+, 5.11% (83) ERα+PR-, 56.86% (924) ERα-PR-
and 8.12% (132) ERα-PR+ (Table 1). The median and
mean ages of the first study group (ERα-PR+) were 47 and
47.04, and those of the second study group (ERα+PR+)
were 50 and 51.0, respectively. Patients’ age was signifi-
cantly lower in the ERα-PR+ group (P=0.002). Only
44.27% (58) of patients in the ERα-PR+ group, while
55.35% (269) of those in the ERα+PR+ group were diag-
nosed after the age of 50 (post-menopausal). As far as
tumor grades were concerned, in the first study group
(ERα-PR+) 6.06% (8) of tumors were graded as grade 1
(well-differentiated), 67.42% (89) as grade 2 (moderately
differentiated) and 26.52% (35) as grade 3 (poorly differ-
entiated). In the second group (ERα+PR+) 9.46% (46) of
tumors were grade 1 (well-differentiated), 76.95% (374)
grade 2 (moderately differentiated) and 12.96% (63) grade
3 (poorly differentiated). A χ2 statistical analysis of grad-
ing revealed no significant difference between the two
study groups (P=0.091), although the ERα-PR+ tumors
were intermediate, containing significantly more poorly
differentiated tumors than the ERα+PR+ group (P=
0.032). Tumor size was significantly larger in the ERα-
PR+ group than in the ERα+ PR+ group (P=0.046). The
mean tumor size in the first study group (ERα-PR+) was
found to be 4.84 cm (SD=3.593) compared to 3.83 cm
(SD=2.76) in the second group (ERα+PR+). 22.7%
(30/132) of patients in the first group and 16.6% (81/486)
of the second group had evidence of axillary lymph node
involvement with a mean number of lymph nodes involved
being 7.3 (SD=7.13) and 8.3 (SD=8.48), respectively
(P=0.107). The frequency of lymph node metastases was
therefore independent of receptor profile (Table 1).
Discussion
The steroid hormone estrogen has important functions in
target tissues and plays a major role in proliferation of tumor
cells in breast and uterus among other organs. Its receptor has
two subtypes, ER-alpha (α) and ER-beta (β),19 the alpha sub-
type being more expressed than the beta subtype.15 ERα and
ERβ both belong to the nuclear receptor superfamily, mem-
bers of which share a common structural architecture. In the
mature mammary gland, ERα is spontaneously observed in
epithelial cells whereas ERβ is more broadly expressed in
epithelial and stromal cells, including fibroblasts and
endothelial cells.33 It is noteworthy that about 50% of breast
cancer patients express both ERα and ERβ.32 The function of
ERβ is thought to counteract that of ERα, with the α subtype
expression leading to an increase in estrogen-stimulated pro-
liferation and the β subtype expression resulting in a decrease
in proliferation and thus a favorable prognosis in breast can-
cer patients. Shaaban et al carried out an immunohistochemi-
cal analysis of 283 samples of breast tissue with 94.3% of
normal breast lobules and 60.0% of invasive cancers showing
subtype β expression.30 In terms of predictive factors for treat-
ment, studies have been done evaluating ERβ mRNA expres-
sion and immunohistochemical staining and also the clinical
response to endocrine therapy, but the studies so far on the β
subtype have been inconclusive and controversial. Hence, we
have focused completely on the α subtype in our study and
the discussion here will also be in this context.
Previous studies using complex binding assays to search
for ER in ER-PR+ tumors have reported some positive
cases.28,35 More recently, immunologic, rather than func-
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Table 1. Immunohistochemical hormone receptor profile
Parameters ERα+PR+ ERα-PR+ P value
No. (%) 486 (29.91) 132(8.12)
Age (mean) 51.0 47.04 0.002*
Tumor grade (%)
1 9.46 6.06 0.576
2 76.95 67.42 0.174
3 12.96 26.52 0.032*
Overall significance 0.091
Tumor size (cm) 3.83 4.84 0.046*
Axillary lymph node 16.6 22.7 0.107
involvement (%)
*p <0.05=significant difference
tional, assays for ER have been developed, using antibod-
ies that can measure both occupied and unoccupied recep-
tors,8 but their definitive role has not yet been established. 
The frequency of immunohistochemically ERα-PR+ breast
carcinomas is generally 2% to 6% of all cases.13,21,25,28,37 The
frequency in the present series (8.12%, 132 patients) is
slightly higher than previously reported. Previous studies
have also suggested that this receptor profile occurs more
commonly in tumors from younger women. In the present
series, the mean age (47.04) of our patients with ERα-PR+
tumors was significantly lower than that of patients with
other receptor profiles.
The other prognostic factors examined in this study also
suggest that ERα-PR+ tumors differ from ERα+PR+ ones.
These tumors were found to be larger and more aggressive
(grade 3) compared to the control group (ERα+PR+). The
higher tumor grade in ERα-PR+ tumors compared with
ERα+PR+ tumors confirms previous reports.21 The pres-
ence of lymph node metastases did not correlate with any
hormone receptor profile and was therefore also consistent
with previous reports.21
Do tumors that truly do not contain ER but contain PR
exist? This remains the central question about steroid
receptors in breast carcinomas. Explanations that have been
proposed include a high level of circulating estrogen in
young women that either causes binding sites on the recep-
tor to be occupied with endogenous ligands or competes
with exogenous ligands in the binding assay.13,25,28,34 The
first is based on the observation that in younger patients the
high levels of circulating estrogens may cause transfer of
the cytoplasmic receptor to the nucleus, causing false low
levels of ER.36 However, several studies have failed to find
an inverse correlation between either circulating or tumor-
cell levels of estrogen and levels of ER.6,7,27,37 The second is
based on the observation of Zava et al39 and Panko and
Macleod22 that certain tumors may have uncharged ER in
the nucleus that may function without estrogens. A third
possible explanation for this phenomenon would be that
such patients were actually ERα+ but endogenous or
exogenous estrogens (e.g. birth control pills) might result in
competition for the radioactive estrogen used in the assay
and so provide a falsely negative ER result. However, there
is evidence to indicate that false-negative ER was not due
to the presence of endogenous estrogens.6,7 One theory pos-
tulates that the ER is abnormal and therefore activates the
estrogen pathway, but does not bind estrogen.11 Still other
possibilities are laboratory error and even the presence of a
true ER-negative, PR-positive state. Evidence from experi-
mental studies suggests that defective ERs may exist,
which may not contain estrogen- or antibody-binding sites,
but which are, nevertheless, capable of stimulating PR syn-
thesis.3,11 Such variant malignant cells would not be estro-
gen-responsive. The presence of a PR gene with abnormal
regulation that functions in the absence of estrogen has also
been reported in a breast carcinoma cell line.29 An investi-
gator34 has argued that all ERα- PR+ tumors should be
regarded as biologically equivalent to ERα+PR+ tumors.
However, the response rate to hormonal therapy for ERα-
PR+ tumors is substantially lower than that of ERα+PR+
ones,21 suggesting real differences between the two hor-
mone receptor profiles.
In conclusion, whatever the cause of ERα-PR+ tumors,
it is apparent that tumors with this hormone receptor pro-
file are heterogeneous. They do not merely reflect tumors
that are actually ERα+PR+, whose ER is masked in bind-
ing assays by endogenous estrogen in younger women.
The present data suggest differences in prognostic factors
compared with ERα+PR+ tumors. The ERα-PR+ tumors
appear to be heterogeneous and biologically different from
ERα+PR+ ones. 
These results also have important clinical implications.
Most clinicians elect to proceed directly to chemotherapy
when the results of estrogen receptor assay are negative.
However, there are a small percentage of women with
ERα- tumor who have been reported to respond to hor-
mones.6 If ERα is negative then it could be falsely
assumed that PR is also negative, but the case could be of
our study group (ERα-PR+). Hence in a clinical setting
both ER and PR should be tested. This could otherwise
result in unnecessary chemotherapy or may deprive the
patient of anti-estrogenic therapy. This should be given
special attention in the case of pre-menopausal women.
Our results suggest that one should be careful to determine
that such women are truly estrogen-receptor-negative,
especially if their progesterone receptors are positive. This
observation stresses the need for better laboratory methods
including increased affinity antibodies to detect these pos-
sibly masked estrogen receptors.
Another important possibility is the presence of ER β
subtype instead of the α subtype. This could lead to an
ERα- and PR+ status in a breast cancer patient. But as
mentioned before, the prognostic indication of the β sub-
type is still not well characterized, nor is its response to
hormonal treatment (the α subtype has a well established
response to hormonal therapy). Thus, this observation
underlies the importance of β subtype detection and the
further studying of its prognostic value and its potential as
a novel target for pharmacological therapy.
These results suggest that information regarding the
menopausal status and the possible administration of
exogenous hormones should be requested by laboratories
before doing estrogen and progesterone receptor evalua-
tions in breast cancer. Finally, and most importantly, we
believe that standardized assays of ER (both α and β sub-
types) and PR should be used internationally to overcome
the artifact problems that already exist among the variety
of current methods and that in all cases both ER (α/β) and
PR should be estimated rather than ER alone.
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